False positivity of anti aquaporin-4 antibodies in natalizumab-treated patients.

Date publication

août 2016

Journal

Multiple sclerosis (Houndmills, Basingstoke, England)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme

Tous les auteurs :
Cohen M, De Sèze J, Marignier R, Lebrun C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/26869528

Résumé

Neuromyelitis optica spectrum disorders (NMOSD) represent a differential diagnosis of multiple sclerosis (MS). Detection of anti-aquaporin-4 antibodies (AQP4-Ab) is the strongest argument to confirm NMOSD. Diagnosing NMOSD is a major concern because specific MS disease modifying drugs can lead to neurological worsening.

Mots clés

Adult, Aquaporin 4, immunology, Autoantibodies, blood, Autoimmunity, Biomarkers, blood, False Positive Reactions, Female, Humans, Immunosuppressive Agents, adverse effects, Male, Multiple Sclerosis, blood, Natalizumab, adverse effects, Predictive Value of Tests, Retrospective Studies, Serologic Tests, Time Factors, Treatment Outcome, Young Adult

Référence

Mult. Scler.. 2016 08;22(9):1231-4